Holen Sie sich die Stockscreener-App
8.99
3.23%
-0.30
Handel nachbörslich:
8.99
Schlusskurs vom Vortag:
$9.29
Offen:
$9.15
24-Stunden-Volumen:
365.94K
Relative Volume:
0.59
Marktkapitalisierung:
$486.28M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-5.6899
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
+0.00%
1M Leistung:
+22.81%
6M Leistung:
+173.25%
1J Leistung:
+153.24%
1-Tages-Spanne:
$8.82
$9.335
1-Wochen-Bereich:
$8.45
$9.89
52-Wochen-Spanne:
$2.315
$9.89
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
8.99 | 502.51M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
How to track smart money flows in Fulcrum Therapeutics Inc.Earnings Risk Summary & High Accuracy Buy Signal Tips - newser.com
What drives Fulcrum Therapeutics Inc stock priceShort Selling Opportunities & Low Cost Market Tips - earlytimes.in
How supply chain issues affect Fulcrum Therapeutics Inc. stock2025 Breakouts & Breakdowns & Safe Capital Growth Plans - Trung tâm Dự báo KTTV quốc gia
How to monitor Fulcrum Therapeutics Inc. with trend dashboardsJuly 2025 Sector Moves & Growth Focused Entry Reports - newser.com
How Fulcrum Therapeutics Inc. stock reacts to Fed rate cuts2025 Biggest Moves & Safe Entry Zone Identification - Trung tâm Dự báo KTTV quốc gia
Will Fulcrum Therapeutics Inc. stock outperform value stocksJuly 2025 Fed Impact & Low Risk High Reward Trade Ideas - Trung tâm Dự báo KTTV quốc gia
Can momentum traders help lift Fulcrum Therapeutics Inc.July 2025 Drop Watch & High Return Trade Opportunity Guides - newser.com
Real time alert setup for Fulcrum Therapeutics Inc. performance2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
How institutional buying supports Fulcrum Therapeutics Inc. stock2025 Analyst Calls & Safe Entry Point Identification - newser.com
Fulcrum Therapeutics Inc. stock volume spike explained2025 Dividend Review & Risk Controlled Daily Trade Plans - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockRate Hike & Reliable Price Breakout Signals - newser.com
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 - The Manila Times
Fulcrum Therapeutics Presents Preclinical Data for FTX-6274 as a Potential Treatment for Castration-Resistant Prostate Cancer - Quiver Quantitative
Pattern recognition hints at Fulcrum Therapeutics Inc. upsideJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
FTX-6274 Poster 2504P: Fulcrum Shows Preclinical Efficacy in CRPC at ESMO Congress Oct 18, 2025 - Stock Titan
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.60 - Defense World
Is Fulcrum Therapeutics Inc. stock poised for growthTrend Reversal & Low Risk Entry Point Guides - newser.com
How to build a dashboard for Fulcrum Therapeutics Inc. stock2025 Short Interest & Reliable Price Action Trade Plans - newser.com
What data driven models say about Fulcrum Therapeutics Inc.’s futureWeekly Stock Analysis & AI Driven Stock Movement Reports - newser.com
What is Leerink Partnrs' Estimate for FULC FY2027 Earnings? - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Leerink Partnrs Has Negative Outlook of FULC FY2027 Earnings - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq - MSN
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oklahoma City NewsThe Oklahoman - FinancialContent
Detecting price anomalies in Fulcrum Therapeutics Inc. with AIIPO Watch & Low Drawdown Investment Strategies - newser.com
What moving averages say about Fulcrum Therapeutics Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Order flow analysis tools used on Fulcrum Therapeutics Inc.2025 Short Interest & Daily Profit Focused Screening - newser.com
Can Fulcrum Therapeutics Inc. recover in the next quarterProduct Launch & High Return Stock Watch Alerts - newser.com
Fulcrum Therapeutics Inc. stock momentum explainedQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Reaches New 12-Month HighHere's What Happened - MarketBeat
Fulcrum Therapeutics, Inc. $FULC Shares Sold by Matisse Capital - MarketBeat
What does recent volatility data suggest for Fulcrum Therapeutics Inc.July 2025 Trends & Community Consensus Picks - newser.com
Technical analysis overview for Fulcrum Therapeutics Inc. stockTrade Ideas & Growth Focused Entry Reports - newser.com
Published on: 2025-10-05 20:19:33 - newser.com
Is Fulcrum Therapeutics Inc. stock trading near support levelsRate Cut & Safe Capital Growth Stock Tips - newser.com
Using flow based indicators on Fulcrum Therapeutics Inc.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Fulcrum Therapeutics Inc. recovery potential after sell offInflation Watch & Safe Entry Point Identification - newser.com
What earnings revisions data tells us about Fulcrum Therapeutics Inc.Weekly Stock Report & Fast Moving Stock Watchlists - newser.com
Can Fulcrum Therapeutics Inc. stock sustain market leadershipJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):